Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience.
10.4174/astr.2018.95.3.147
- Author:
Jong Man KIM
1
;
Kwang Woong LEE
;
Dong Hyun SINN
;
Gyu Seong CHOI
;
Nam Joon YI
;
Choon Hyuck David KWON
;
Kyung Suk SUH
;
Jae Won JOH
Author Information
1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Safety;
Antiviral agents;
Liver transplantation;
Treatment outcome
- MeSH:
Anemia;
Antiviral Agents*;
Asia;
Hepacivirus*;
Hepatitis C*;
Hepatitis*;
Humans;
Korea*;
Liver Transplantation;
Liver*;
Recurrence;
RNA;
Transplant Recipients*;
Treatment Failure;
Treatment Outcome
- From:Annals of Surgical Treatment and Research
2018;95(3):147-151
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The proportion of liver recipients with HCV is gradually increasing in Korea. Limited data are available regarding the efficacy of direct antiviral agents (DAAs) in liver transplant recipients in Asia. We aimed to assess the efficacy and safety of DAAs in HCV-infected liver recipients in Korea. METHODS: Forty HCV-infected patients from 2 centers received DAAs in the pretransplant or posttransplant period between May 2015 and November 2016. RESULTS: DAA was administered in the pretransplant period in 6 patients and the posttransplant period in 34 patients. Dalastavir and asunaprevir (n = 2) and sofosbuvir/ledipasvir and ribvarin (n = 4) were used in the pretransplant period. HCV RNA was not detected before liver transplantation in all patients. Sustained virological response (SVR) at 12 and 24 weeks after liver transplantation was 100%. In the posttransplant period, 33 of 34 patients received sofosfovir-based therapy. SVR at 12 weeks in those patients was 94%. Recurrent virologic relapse developed in 2 patients because of HCC recurrence or treatment failure. Adverse events included anemia (n = 2) and abdominal discomfort (n = 1). CONCLUSION: DAAs are an effective and well-tolerated treatment for HCV-infected recipients in Korea.
